Jam

Albertsons Cos. (NYSE: ACI) offers prescription transfer support to Rite Aid customers following its bankruptcy, providing a $15 discount on $75+ groceries for first-time transfers and $15 savings every five refills. Customers can use the Sincerely Health platform for prescriptions, telehealth, and vaccine scheduling (covering flu, COVID-19, etc.), earning $20 off $200+ purchases per administration. The company also extends employment opportunities to displaced Rite Aid workers across 2,270 stores, leveraging its national 1,700-pharmacy network and proximity integration to ensure healthcare continuity. Operating in 34 states, Albertsons combines scale with localized service, supported by 22 distribution hubs and $435M in 2024 community aid.

AECOM partners with Saudi Arabia’s Ministry of Sport to modernize Riyadh’s King Fahd Sports City for the 2027 AFC Asian Cup and 2034 FIFA World Cup. Upgrading the 1987 “Pearl of Stadiums” to meet FIFA standards, the project aligns with Vision 2030 goals to diversify the economy, potentially increasing tourism revenue by $40 billion by 2030. AECOM’s expertise in global stadium projects, alongside its Middle East and U.S. teams, will integrate sustainability and smart technologies while enhancing community connectivity. The overhaul supports Saudi Arabia’s ambition to become a premier sports hub and strengthens its non-oil economic strategy.

Teva Pharmaceutical Industries has initiated a $2 billion refinancing through euro and dollar-denominated bonds via Dutch subsidiaries to restructure $2 billion in debt maturing between 2026-2031 (including high-coupon sustainability-linked notes). Leveraging current favorable market conditions, the move extends maturities, lowers interest costs, and maintains the parent company’s unconditional guarantees to ensure investor confidence. While introducing modest structural complexity, the strategy aligns with industry-wide debt optimization practices, mirroring recent Big Pharma restructurings.

Alvotech, a global biosimilar medicines developer, commenced trading on Nasdaq Stockholm on May 19, 2025, via an oversubscribed SDR offering (441,600 SDRs at SEK 87.51 each, raising SEK 39M). This triple-listing (including Nasdaq Global and Iceland) enhances liquidity and European investor access, while the pending acquisition of Xbrane Biopharma’s R&D operations in Sweden supports scientific expansion. Despite a 10% SDR price discount and added operational complexity, the move aims to strengthen Nordic presence, diversify funding sources, and capitalize on robust biotech investment interest in Europe.

Halliburton introduced EarthStar 3DX, the first 3D ultra-deep horizontal look-ahead resistivity service, enabling real-time geological mapping 50 feet ahead of drill bits. This innovation allows proactive trajectory adjustments in challenging environments, reducing costly sidetracking and wellbore instability risks, especially in unconventional plays like Permian and Eagle Ford. Integrated with the iStar drilling platform, it competes against Schlumberger’s DELFI and Baker Hughes’ Adventure™, aligning with sustainability goals by enabling longer laterals with lower carbon intensity amid tightening industry margins and regulations. 98 words.

BGC Group launched FMX Futures Exchange on May 18, 2025, introducing 2- and 5-year U.S. Treasury futures with ten top institutions. Partnering with LCH Limited enables cross-margining efficiencies, integrating BGC’s existing cash Treasuries and FX platforms to create a multi-asset risk management ecosystem. The move angles to challenge CME’s dominance (85% market share) by offering tech-driven pricing and algorithmic tools, while addressing regulatory scrutiny of vertically integrated exchanges. With 17 asset classes and 2,000+ global institutions, the Infrastructure & Exchanges segment now underpins BGC’s Q2 earnings outlook.

Innovent Biologics released its 2024 ESG Report outlining a five-pillar strategy—Excellent Governance, Advancing Public Health, Uncompromising Quality, Empowering Talent, and Sustainable Ecology. Achieving an MSCI AAA ESG rating (the only Chinese biotech recipient), it aligned with UN SDGs, expanded board diversity, and distributed RMB 3.6 billion in medicines to 200,000+ patients. The company maintained 100% GMP compliance, reduced energy use by 29%, saved 51,100 tons of water annually, and achieved 96.8% employee retention with 44.2% women in management roles. Its pipeline includes 13 orphan drugs and three New Drug Applications under review, underscoring its dual focus on innovation and sustainability.

A federal jury in Santa Ana ruled in favor of medical device reprocessor Innovative Health in its antitrust case against Johnson & Johnson, finding subsidiary Biosense Webster illegally withheld clinical support from hospitals using reprocessed single-use devices (SUDs). The verdict affirms hospitals’ legal right to adopt FDA-regulated SUDs, promoting cost efficiency, sustainability, and fair competition while challenging anticompetitive tactics by original equipment manufacturers. The outcome is seen as a catalyst to dismantle practices inflating healthcare costs and stifling innovation.

Savara Inc. announced positive Phase 3 trial results for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) at ATS 2025. In 157 patients, the therapy significantly reduced radiological surfactant burden (mean GGO score decrease 2.1 vs. 1.1; P=0.0004) and need for rescue whole-lung lavage (7.4% vs. 13.3%). Molgramostim improved respiratory quality of life metrics (St. George’s Respiratory Questionnaire, P=0.0084) and reduced breathing difficulties (P=0.0305 and P=0.0049 at Weeks 24/48). By addressing impaired GM-CSF signaling, this inhaled therapy could redefine aPAP treatment, offering a non-invasive alternative to current procedures. Trial data supports future regulatory submissions for rare disease approval pathways.

The Volvo Group mourns Andrea Fuder, Chief Purchasing Officer and Executive Board member since 2017, who passed away following a short illness. She drove transformative procurement strategies, navigating pandemic supply chain crises, semiconductor shortages, and geopolitical trade challenges while advancing Volvo’s carbon-neutral transportation goals through strategic supplier partnerships. CEO Martin Lundstedt praised her legacy of turning obstacles into progress, noting a significant void in leadership. Jens Holtinger, Executive Vice President of Group Trucks Operations, assumes the Acting Chief Purchasing Officer role. Volvo continues expanding its $48 billion market presence across 190 countries, leveraging 100,000 employees to pursue its Vision 2030 sustainability platform.